Studio Investment Management LLC Has $294,000 Stock Position in Pfizer Inc. (NYSE:PFE)

Studio Investment Management LLC reduced its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 55.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 11,074 shares of the biopharmaceutical company's stock after selling 13,631 shares during the quarter. Studio Investment Management LLC's holdings in Pfizer were worth $294,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Sender Co & Partners Inc. lifted its stake in shares of Pfizer by 29.8% in the fourth quarter. Sender Co & Partners Inc. now owns 11,056 shares of the biopharmaceutical company's stock worth $293,000 after acquiring an additional 2,535 shares during the period. Sherbrooke Park Advisers LLC acquired a new position in shares of Pfizer in the fourth quarter worth approximately $1,329,000. Sig Brokerage LP acquired a new position in shares of Pfizer in the fourth quarter worth approximately $1,102,000. Rafferty Asset Management LLC lifted its stake in shares of Pfizer by 11.4% in the fourth quarter. Rafferty Asset Management LLC now owns 656,744 shares of the biopharmaceutical company's stock worth $17,423,000 after acquiring an additional 67,007 shares during the period. Finally, Raiffeisen Bank International AG acquired a new position in shares of Pfizer in the fourth quarter worth approximately $1,027,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have weighed in on PFE. Cantor Fitzgerald began coverage on Pfizer in a report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 target price for the company. UBS Group lifted their target price on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. Citigroup reiterated a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. The Goldman Sachs Group reiterated a "neutral" rating and issued a $25.00 target price (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Finally, Guggenheim reiterated a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have given a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $29.17.

Pfizer Trading Up 1.0%

NYSE PFE opened at $22.83 on Friday. The company has a market cap of $129.77 billion, a price-to-earnings ratio of 16.19, a P/E/G ratio of 0.64 and a beta of 0.58. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.54. The business has a 50 day moving average price of $23.65 and a 200-day moving average price of $25.34.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. During the same quarter in the prior year, the company posted $0.82 earnings per share. Pfizer's revenue was down 7.8% compared to the same quarter last year. As a group, equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.72 annualized dividend and a yield of 7.54%. Pfizer's dividend payout ratio (DPR) is currently 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.